Bayer says it has completed the sale of its animal health business unit to Elanco Animal Health (Greenfield, Indiana), after the fulfilment of closing conditions, including the receipt of regulatory approvals.
Bayer received $5.17 billion in cash, before tax and after deduction of customary purchase price adjustments, together with 72.9 million shares of Elanco Animal Health common stock, corresponding to 15.5% of its outstanding stock, the company says. The shares are subject to certain retention periods until mid-2021, but Bayer maintains its intention to divest the stake in Elanco in due course, it says.
“This transaction creates one of the global animal health leaders,” says Werner Baumann, chairman of Bayer.
Under the terms of the agreement with Elanco, all Bayer animal health employees will have at least one year of employment protection against unilateral termination with similar and no less favorable benefits in the aggregate, Bayer says.
Divesting the animal health business is the largest transaction in a series of portfolio measures Bayer initiated in November 2018 following its $63-billion acquisition of Monsanto.
By: Sotirios Frantzanas
Source: Chemical Week
The total contract value is approximately €430 million. The project scope of work entails complete engineering services, equipment and material supply, installation and construction activities and, as an optional part of the scope, commissioning and start up.
Once it has implemented this project, Lenzing will have biological wastewater treatment plants that meet the best available techniques (BAT) quality standard at all its production sites.
The debate over the position of hydrogen in the new energy revolution has come to the fore again thanks to Japan’s hosting of the Olympic Games. But rather than showcasing how green this miracle new fuel is, it has highlighted its many problems.
